Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex Pharmaceuticals

485.72
-5.9200-1.20%
Post-market: 485.34-0.3800-0.08%18:50 EST
Volume:1.33M
Turnover:644.25M
Market Cap:124.73B
PE:-233.52
High:491.62
Open:490.15
Low:479.78
Close:491.64
Loading ...

Vertex Pharmaceuticals: Mixed Financial Performance and Future Prospects Lead to Hold Rating

TIPRANKS
·
11 Feb

Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $445 From $441, Maintains Market Perform Rating

MT Newswires Live
·
11 Feb

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Axsome Therapeutics (AXSM) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
11 Feb

Vertex Pharmaceuticals price target raised to $467 from $435 at Barclays

TIPRANKS
·
11 Feb

Vertex Pharmaceuticals (VRTX) Receives a Hold from Barclays

TIPRANKS
·
11 Feb

Vertex Pharmaceuticals Inc (VRTX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
11 Feb

Evercore ISI Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
11 Feb

Vertex Pharmaceuticals Inc : RBC Raises Target Price to $407 From $402

THOMSON REUTERS
·
11 Feb

Vertex Pharmaceuticals (VRTX) Sees Strong 2025 Revenue Growth

TIPRANKS
·
11 Feb

Positive Outlook for Vertex Pharmaceuticals: Strong Cystic Fibrosis Performance and Promising Product Launches Drive Buy Rating

TIPRANKS
·
11 Feb

Vertex Pharmaceuticals Reports Strong 2024 Revenue Growth

TIPRANKS
·
11 Feb

Vertex Pharmaceuticals Inc : Truist Securities Raises Target Price to $520 From $460

THOMSON REUTERS
·
11 Feb

Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
11 Feb

Vertex Minerals Strengthens Board with New Appointment

TIPRANKS
·
11 Feb

Vertex Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Feb

Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates

Zacks
·
11 Feb